teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 11 Projects Releases Packages Wiki Activity Actions 67

extract: 2026-02-01-glp1-patent-cliff-generics-global-competition

Browse source 
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
This commit is contained in:
Teleo Agents 2026-03-16 15:44:18 +00:00
parent af067944f1
commit 4a40ec4017
2 changed files with 29 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

12
domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md
View file

@ -53,6 +53,18 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir
At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated.
### Additional Evidence (challenge)
*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16*
International generic competition beginning in 2026 will compress prices far faster than the 'inflationary through 2035' timeline assumes. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026. China has 17+ Phase 3 generic candidates targeting $40-$50/month pricing. India patents expire March 2026. Even accounting for US regulatory delays (patents extend to 2031-2032), international price arbitrage and compounding pharmacy pressure will accelerate US price compression. At $40-$50/month (95% below current US pricing), GLP-1s become unambiguously cost-effective under any payment model, fundamentally changing the cost trajectory calculation.
### Additional Evidence (extend)
*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-16*
Oral Wegovy launched January 2026 at $149-$299/month (Medicare negotiated to $245/month), representing 50-83% price reduction from injectable formulations before generic competition. This suggests the price compression curve is steeper than linear patent expiry would predict, as oral formulations create competitive pressure independent of generic entry. The combination of oral formulation competition (2026) and international generics (2026-2030) followed by US generics (2031-2033) creates a three-phase price decline rather than a single cliff.
---
Relevant Notes:

18
inbox/archive/2026-02-01-glp1-patent-cliff-generics-global-competition.md
View file

@ -7,9 +7,13 @@ date: 2026-02-01
domain: health
secondary_domains: [internet-finance]
format: article
status: unprocessed
status: enrichment
priority: medium
tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
processed_by: vida
processed_date: 2026-03-16
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
extraction_model: "anthropic/claude-sonnet-4.5"
---
## Content
@ -50,3 +54,15 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
## Key Facts
- Semaglutide patents extend to 2031-2032 in US and Europe
- Canada's semaglutide patents expired January 4, 2026
- Brazil generic competition opens March 2026
- India semaglutide patents expire March 2026
- China has 17+ generic semaglutide candidates in Phase 3 trials
- Oral Wegovy launched January 2026 at $149-$299/month
- Medicare negotiated oral Wegovy price: $245/month
- Sandoz, Apotex, and Teva filed for Canadian generic semaglutide immediately after patent expiry
- Biomm + Biocon (India) preparing generic semaglutide for Brazil market